86
Participants
Start Date
November 20, 2024
Primary Completion Date
December 1, 2026
Study Completion Date
June 1, 2027
Experimental
Radiation: 30Gy/15F Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2,D1 or 130mg/m2,D1,8 IV Q3W
Active comparator
Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2,D1 or 130mg/m2,D1,8 IV Q3W
RECRUITING
Anhui Provincial Cancer Hospital, Hefei
Anhui Provincial Cancer Hospital
OTHER